XML 34 R22.htm IDEA: XBRL DOCUMENT
v3.24.3

WARRANTS AND SHAREHOLDERS' EQUITY | 9 Months Ended
--- | ---
Sep. 30, 2024
WARRANTS AND SHAREHOLDERS' EQUITY |
WARRANTS AND SHAREHOLDERS' EQUITY | NOTE 14 – WARRANTS AND SHAREHOLDERS’ EQUITY Share Repurchase Program and Treasury Stock On May 7, 2023, the Company’s Board of Directors authorized a stock repurchase program that provides for the repurchase of up to $80,000 of its common stock, including any applicable excise tax. On December 7, 2023, the Board of Directors authorized an amendment to the program to increase the authorized amount of repurchases to an aggregate amount not to exceed $250,000, including the amount that remained available as of December 7, 2023 to repurchase common stock under, but not any prior repurchases effected pursuant to, the previous authorization, and any applicable excise tax. The amended authorization expires on December 31, 2025. The program is intended to offset the impact of dilution from the issuance of new shares as part of employee compensation programs. Any share repurchases under this stock repurchase program may be made through open market transactions, privately negotiated transactions or other means including in accordance with Rule 10b-18 and/or Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The timing and total amount of repurchases is subject to business and market conditions and the Company’s discretion. During the three and nine months ended September 30, 2024, the Company repurchased 3,748,301 and 22,993,198 shares of its common stock for $21,351 and $119,107 at a weighted average cost of $5.67 and $5.16 per share, respectively. During the three and nine months ended September 30, 2023, the Company repurchased 2,738,092 and 6,939,117 shares of its common stock for $15,034 and $34,759 at a weighted average cost of $5.47 and $4.99 per share, respectively. As of September 30, 2024, a total of $121,537 remained available for future repurchases of the Company’s common stock under the program. Warrants The Company had publicly traded warrants that were assumed upon the closing of the business combination with FTAC Olympus Acquisition Corp. in June 2021, and were exercisable for shares of the Company’s common stock. Warrants were only exercisable for a whole number of shares at an exercise price of $11.50 and would expire on June 25, 2026, or earlier, if redeemed. In September 2024, the Company completed a tender offer (the “Offer”) to repurchase all outstanding Warrants, at $0.78 per Warrant. Concurrently with the Offer, the Company solicited consents (the “Consent Solicitation”) from holders of its outstanding Warrants to amend the agreement governing the Warrants (the “Warrant Agreement”) to permit the Company to redeem all Warrants that remained outstanding after the completion of the Offer for $0.70 per Warrant in cash, without interest. ​ ​ NOTE 14 – WARRANTS AND SHAREHOLDERS’ EQUITY (continued): The Offer expired on September 9, 2024 (the “Expiration Date”), in accordance with its terms. 24,030,937 Warrants were validly tendered and not validly withdrawn from the Offer representing approximately 95.5% of the then-outstanding Warrants. These Warrants were repurchased for $0.78 per Warrant, or $18,744 in total, with a $13,217 loss recognized upon repurchase, which is the result of the premium paid above the valuation of the Warrants as of the latest revaluation date of June 30, 2024. On September 10, 2024, the Company issued a notice of redemption to redeem all remaining untendered and outstanding Warrants for $0.70 per Warrant as of September 25, 2024. These Warrants were redeemed for $0.70 per Warrant, or $789 in total, with a $530 loss recognized upon repurchase, which is the result of the premium paid above the valuation of the Warrants as of the latest revaluation date of June 30, 2024. The Company also incurred approximately $1,000 in expenses associated with the transaction, which are included in loss on warrant repurchase/redemption in the condensed consolidated statements of comprehensive income. The Warrants were accounted for as liabilities in accordance with ASC 815-40, Derivatives and Hedging, and were presented within warrant liabilities on the condensed consolidated balance sheets. The warrant liabilities were measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the condensed consolidated statements of comprehensive income. The following table presents the changes in the fair value of warrant liabilities (Level 1): ​
​ | ​ | ​ | ​
​ |  | Warrant
​ | ​ | Liability
Fair value as of December 31, 2023 | ​ | $ | 8,555
Change in fair value | ​ | ​ | (2,767)
Repurchase and redemption | ​ |  | (5,788)
Fair value as of September 30, 2024 | ​ | $ | —
​ | ​ | ​ | ​
Fair value as of December 31, 2022 | ​ | $ | 25,914
Change in fair value | ​ | ​ | (5,535)
Fair value as of September 30, 2023 | ​ | $ | 20,379
​ ​ Accumulated Other Comprehensive Income (Loss) The changes in the balances of each component of accumulated other comprehensive income, net of tax, for the three and nine months ended September 30, 2024 were as follows. There were no changes in other comprehensive income (loss) in the three or nine months ended September 30, 2023: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended September 30, 2024
​ | ​ | Foreign currency translation adjustments | ​ | Unrealized gains on available-for-sale debt securities | ​ | Unrealized gains (losses) on cash flow hedges | ​ | Total
Beginning balance | ​ | $ | (176) | ​ | $ | 871 | ​ | $ | (545) | ​ | $ | 150
Other comprehensive income before reclassifications | ​ | ​ | — | ​ | ​ | 9,440 | ​ | ​ | 793 | ​ | ​ | 10,233
Amount of loss reclassified from AOCI | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 164 | ​ | ​ | 164
Net current period other comprehensive income | ​ |  | — | ​ |  | 9,440 | ​ |  | 957 | ​ |  | 10,397
Ending balance | ​ | $ | (176) | ​ | $ | 10,311 | ​ | $ | 412 | ​ | $ | 10,547
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended September 30, 2024
​ | ​ | Foreign currency translation adjustments | ​ | Unrealized gains on available-for-sale debt securities | ​ | Unrealized gains on cash flow hedges | ​ | Total
Beginning balance | ​ | $ | (176) | ​ | $ | — | ​ | $ | — | ​ | $ | (176)
Other comprehensive income before reclassifications | ​ | ​ | — | ​ | ​ | 10,311 | ​ | ​ | 20 | ​ | ​ | 10,331
Amount of loss reclassified from AOCI | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 392 | ​ | ​ | 392
Net current period other comprehensive income | ​ |  | — | ​ |  | 10,311 | ​ |  | 412 | ​ |  | 10,723
Ending balance | ​ | $ | (176) | ​ | $ | 10,311 | ​ | $ | 412 | ​ | $ | 10,547
​

X
- References No definition available. + Details
Name: | payo_DisclosureOfTemporaryEquityAndShareBasedPaymentArrangementAbstract
Namespace Prefix: | payo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for mezzanine equity and stock-based compensation. + References No definition available. + Details
Name: | payo_DisclosureOfTemporaryEquityAndShareBasedPaymentArrangementTextBlock
Namespace Prefix: | payo_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration